|
|
FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF ... - Business Wire (press release) |
Business Wire (press release)
FibroGen enrolled anemic Stage 5 CKD patients [end-stage renal disease (ESRD)] on hemodialysis therapy in a phase 2a dose-escalation study to evaluate the ability of these patients to maintain and/or to correct hemoglobin levels when converted from
|
|
|
Satellite Laboratory Services changes name - NephrOnline |
NephrOnline
“We are not the same company we were in 2000 when we began providing ESRD laboratory testing to the independent market. Our laboratory business remains our core and our commitment to quality and service has not changed.
|
|
Study: Advances in kidney disease care not benefitting diabetes patients - Endocrine Today |
Endocrine Today
According to an accompanying editorial by Robert G. Nelson, MD, of the National Institute of Diabetes and Digestive and Kidney Diseases in Phoenix, the incidence rate of ESRD in black patients is about fourfold higher than in white patients.
|
|
KAI Starts Secondary Hyperparathyroidism Drug Study - Renal Business Today |
Renal Business Today
Results obtained in the study will be used to select the appropriate dosing regimen for further development of KAI-4169 for the chronic management of SHPT in ESRD patients. Previous Phase 1 data demonstrated that single IV doses of KAI-4169 were safe
|
|
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with ... - 7thSpace Interactive (press release) |
7thSpace Interactive (press release)
As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced in patients with hepatic or renal impairment, leading to greater drug exposure. Methods: Open-label studies investigated the PK and tolerability of zibotentan in
|
|
|
|
|
<< Start < Prev 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 Next > End >>
|
|
Page 1016 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
